Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.

Mats Christian Højbjerg LassenNiklas Dyrby JohansenDaniel ModinAndrei-Mircea CatarigBodil Kjeldgaard VistisenHanan AmadidEsther ZimmermannGunnar GislasonTor Biering-Sørensen

Published in: Diabetes, obesity & metabolism (2024)

Approximately one in five patients discontinued GLP-1RA therapy within the first 12 months and only half were adherent. Overall, lower socioeconomic status and higher comorbidity burden were associated with higher risk of discontinuing GLP-1RA treatment.

Keyphrases

rheumatoid arthritis
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
type diabetes
disease activity
metabolic syndrome
skeletal muscle
mesenchymal stem cells
cross sectional
patient reported outcomes
weight loss